TrialHaematologica2024

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.

Todd A Fehniger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.